Cantor Fitzgerald’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
Other funds holding LCTX
Cantor Fitzgerald's LCTX Position: Q3 2026 in Review
Cantor Fitzgerald opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 12,000 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #756 among its holdings.
143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.
- Cantor Fitzgerald held 12,000 shares of Lineage Cell Therapeutics worth $11.4K as of Q3 2026.
- Lineage Cell Therapeutics was a new Cantor Fitzgerald position in Q3 2026.
- Lineage Cell Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q3 2026, its #756 holding.
- 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.
Based on Cantor Fitzgerald's 13F filing for Q3 2026, filed 16 Nov 2026.